Acumen Pharma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
3 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sabirnetug IV (ACU193 IV) / Acumen Pharma
ALTITUDE-AD, NCT06335173: A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants with Early Alzheimer's Disease

Active, not recruiting
2
540
Europe, Canada, US
sabirnetug, Placebo
Acumen Pharmaceuticals
Alzheimer Disease
10/26
10/26
INTERCEPT-AD, NCT04931459: A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD

Completed
1
65
US
ACU193, Placebo
Acumen Pharmaceuticals, National Institute on Aging (NIA)
Alzheimer Disease
06/23
06/23
ACU193-102, NCT06511570: A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants

Completed
1
28
US
sabirnetug (ACU193), Sabirnetug + rHuPH20
Acumen Pharmaceuticals
Alzheimer Disease
09/24
09/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sabirnetug IV (ACU193 IV) / Acumen Pharma
ALTITUDE-AD, NCT06335173: A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants with Early Alzheimer's Disease

Active, not recruiting
2
540
Europe, Canada, US
sabirnetug, Placebo
Acumen Pharmaceuticals
Alzheimer Disease
10/26
10/26
INTERCEPT-AD, NCT04931459: A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD

Completed
1
65
US
ACU193, Placebo
Acumen Pharmaceuticals, National Institute on Aging (NIA)
Alzheimer Disease
06/23
06/23
ACU193-102, NCT06511570: A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants

Completed
1
28
US
sabirnetug (ACU193), Sabirnetug + rHuPH20
Acumen Pharmaceuticals
Alzheimer Disease
09/24
09/24

Download Options